Published in

Pakistan Journal of Medical and Health Sciences, 5(16), p. 514-516, 2022

DOI: 10.53350/pjmhs22165514

American College of Physicians, Annals of Internal Medicine, 4(175), p. 490-498, 2022

DOI: 10.7326/m21-3498

Links

Tools

Export citation

Search in Google Scholar

Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Introduction: Globally, cardiovascular disease is the main contributor to mortality, accounting for about 17.5 million deaths, or 46.2% of deaths from non-communicable diseases. Objectives: The main objective of the study is to find the diabetes-related complications and mortality in patients with atrial fibrillation receiving different oral anticoagulants. Material and methods: This cross sectional study was conducted in DHQ Teaching Hospital Sahiwal during July 2021 till December 2021. The data were collected from 120 diabetic patients who diagnosed with AF. After permission from hospital ethical committee, total 120 patients meeting the inclusion and exclusion criteria was enrolled in the study. Detailed history of DM and physical examination was done to meet the inclusion and exclusion criteria. Results: The data was collected from 120 patients. Out of 120 participants, 60 were treated with warfarin while 60 were considered as control group. Median age was 26 years in the group I and 25.3 years in the group II (p=0.705). Female cases counted for 41 (86%) and 19 (14%) in I and II groups, respectively. Conclusion: It is concluded that patients with AF and diabetes have a high overall cardiovascular risk. Non–vitamin K antagonist oral anticoagulants were associated with lower hazards of diabetes complications and mortality than warfarin in patients with AF and DM.